Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
With a market cap of 4.74B, Alkermes(ALKS) trades at $28.00. The stock has a price-to-earnings ratio of 14.48.
During the trading day, Alkermes(ALKS) stock saw an opening price of $29.02, a peak of —, and a bottom of —.
Trading volume for Alkermes(ALKS) stock has reached 0, versus its average volume of 3.31M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
H.C. Wainwright analyst Douglas Tsao has reiterated their neutral stance on ALKS stock, giving a Hold rating on November 12. TipRanks Black Friday Sale Claim 60...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
(RTTNews) - Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said they have agreed to the terms of an increased offer under which Alkermes...
Analyst ratings
81%
of 16 ratingsMore ALKS News
Alkermes (ALKS) and Avadel Pharmaceuticals (AVDL) announced that the companies have reached agreement on the terms of an increased recommended offer under which...
Truist raised the firm’s price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk th...
Danish drugmaker H. Lundbeck has made an unsolicited bid worth up to $2.25 billion for Avadel Pharmaceuticals. Carsten Snejbjerg/Bloomberg News Danish drugmake...
Alkermes (ALKS) notes the announcement made by Avadel Pharmaceuticals (AVDL) regarding a possible offer by H. Lundbeck A/S to acquire all the issued and to be i...
Alkermes (ALKS) shared positive topline data from its Vibrance-2 phase 2 study evaluating alixorexton in narcolepsy type 2. The study showed clinically meaningf...
